Incyte Announces Pivotal REACH2 Study Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi®) versus Best Available Therapy in Patients with Acute Graft-Versus-Host Dis...
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Business Wire
- Phase 3 REACH2 data demonstrate that ruxolitinib (Jakafi®) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy (BAT)- Results show a significantly greater overall response rate (ORR) in patients treated with ruxolitinib (62%) compared to BAT (39%) 1,2- GVHD is a serious and common complication of allogeneic stem cell transplants with a one-year mortality rate as high as 80% in patients who develop acute GVHD3-5- The results, published in The New England Journal of Medicine, were also selected for an oral presentation during the Presidential Symposium at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting to be held 30 August to 2 September in Madrid, Spain WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that data from the Phase 3 REACH2 study have been published in The New England Journal of Medicine demonstrating tha
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte (INCY) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c+)" to "buy (b-)".MarketBeat
- Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
- Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata [Yahoo! Finance]Yahoo! Finance
- Does Incyte's 2025 Beat And 2026 Guidance Shift The Bull Case For INCY? [Yahoo! Finance]Yahoo! Finance
- Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 2/10/26 - Beat
INCY
Sec Filings
- 2/23/26 - Form 4
- 2/19/26 - Form 144
- 2/10/26 - Form SCHEDULE
- INCY's page on the SEC website